Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations.

IF 2.7 3区 医学 Q3 ONCOLOGY
Soumya M Turaga, Stacey L Hembruff, Masha G Savelieff, Arnab Ghosh, Rajni V Puri, Harsh B Pathak, Linda J Paradiso, Thomas J Myers, Ao Li, Andrew K Godwin
{"title":"Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations.","authors":"Soumya M Turaga, Stacey L Hembruff, Masha G Savelieff, Arnab Ghosh, Rajni V Puri, Harsh B Pathak, Linda J Paradiso, Thomas J Myers, Ao Li, Andrew K Godwin","doi":"10.1007/s00432-025-06152-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Epithelial ovarian cancers (EOCs) are often diagnosed at an advanced stage, leading to poor survival outcomes despite chemotherapeutic and surgical advances. Precision oncology strategies have been developed to treat EOCs characterized by BRCA1 and BRCA2 inactivation with consequent homologous recombination (HR) repair defects. HR deficiency enhances tumor sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis), approved for EOCs as maintenance therapy, although they have been discontinued as recurrent EOC monotherapy. However, combination treatment with PARPis may be a viable alternate strategy for EOCs. Moreover, EOC patients with wild-type BRCA are ineligible for PARPs, necessitating novel approaches. We previously discovered that inhibiting Aurora kinase A (AURKA) downregulates PARP and BRCA1/2 expression in EOCs and may constitute a viable approach for EOCs.</p><p><strong>Methods: </strong>Herein, we evaluated combined PARPi olaparib with the selective AURKA inhibitor (AURKAi) VIC-1911 in six different patient-derived xenograft (PDX) EOC models, including two with mutant BRCA1, two with mutant BRCA2, one with mutant BRCA1/2, and one with wild-type BRCA1/2.</p><p><strong>Results: </strong>We found that combined olaparib + VIC-1911 treatment reduced tumor volumes and weights by up 90% in some PDX models, with synergistic effect compared to olaparib and VIC-1911 monotherapy. Additionally, combined olaparib + VIC-1911 treatment improved survival of mice harboring both mutant BRCA1 and wild-type BRCA1/2 PDXs. Generally, mice tolerated the drug combinations well during treatment, though loss of body weight was observed at higher drug dosages and with intensive treatment regimens.</p><p><strong>Conclusion: </strong>Our studies indicate a synergistic benefit from combined PARPi and AURKAi in mutant and wild-type BRCA EOC tumors.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"124"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06152-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Epithelial ovarian cancers (EOCs) are often diagnosed at an advanced stage, leading to poor survival outcomes despite chemotherapeutic and surgical advances. Precision oncology strategies have been developed to treat EOCs characterized by BRCA1 and BRCA2 inactivation with consequent homologous recombination (HR) repair defects. HR deficiency enhances tumor sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis), approved for EOCs as maintenance therapy, although they have been discontinued as recurrent EOC monotherapy. However, combination treatment with PARPis may be a viable alternate strategy for EOCs. Moreover, EOC patients with wild-type BRCA are ineligible for PARPs, necessitating novel approaches. We previously discovered that inhibiting Aurora kinase A (AURKA) downregulates PARP and BRCA1/2 expression in EOCs and may constitute a viable approach for EOCs.

Methods: Herein, we evaluated combined PARPi olaparib with the selective AURKA inhibitor (AURKAi) VIC-1911 in six different patient-derived xenograft (PDX) EOC models, including two with mutant BRCA1, two with mutant BRCA2, one with mutant BRCA1/2, and one with wild-type BRCA1/2.

Results: We found that combined olaparib + VIC-1911 treatment reduced tumor volumes and weights by up 90% in some PDX models, with synergistic effect compared to olaparib and VIC-1911 monotherapy. Additionally, combined olaparib + VIC-1911 treatment improved survival of mice harboring both mutant BRCA1 and wild-type BRCA1/2 PDXs. Generally, mice tolerated the drug combinations well during treatment, though loss of body weight was observed at higher drug dosages and with intensive treatment regimens.

Conclusion: Our studies indicate a synergistic benefit from combined PARPi and AURKAi in mutant and wild-type BRCA EOC tumors.

Aurora Kinase A和poly (adp -核糖)聚合酶的双重靶向治疗卵巢癌:临床前评估
目的:上皮性卵巢癌(EOCs)通常在晚期被诊断出来,尽管化疗和手术进展,但导致生存结果不佳。精确的肿瘤学策略已经被开发出来,用于治疗以BRCA1和BRCA2失活为特征的EOCs,随之而来的同源重组(HR)修复缺陷。HR缺乏增强肿瘤对聚(adp -核糖)聚合酶(PARP)抑制剂(PARPis)的敏感性,PARPis被批准用于EOC的维持治疗,尽管它们已被停止作为复发性EOC的单药治疗。然而,联合PARPis治疗EOCs可能是一种可行的替代策略。此外,患有野生型BRCA的EOC患者不适合parp,因此需要新的治疗方法。我们之前发现,抑制极光激酶A (AURKA)可下调EOCs中PARP和BRCA1/2的表达,这可能是一种可行的EOCs治疗方法。方法:在此,我们评估了PARPi olaparib与选择性AURKA抑制剂(AURKAi) VIC-1911在六种不同的患者来源的异种移植(PDX) EOC模型中的联合应用,包括两种突变BRCA1,两种突变BRCA2,一种突变BRCA1/2和一种野生型BRCA1/2。结果:我们发现,与奥拉帕尼和VIC-1911单药治疗相比,奥拉帕尼+ VIC-1911联合治疗在一些PDX模型中使肿瘤体积和重量减少了90%以上,具有协同效应。此外,奥拉帕尼+ VIC-1911联合治疗可提高携带突变型BRCA1和野生型BRCA1/2 PDXs的小鼠的存活率。一般来说,小鼠在治疗期间对药物组合耐受良好,尽管在较高的药物剂量和强化治疗方案下观察到体重减轻。结论:我们的研究表明,PARPi和AURKAi联合治疗突变型和野生型BRCA EOC肿瘤具有协同效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
2.80%
发文量
577
审稿时长
2 months
期刊介绍: The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信